Substitution of antithrombin III in shock and DIC: a randomized study.
In 51 shock patients with DIC Antithrombin III (AT III) substitution, heparin or a combination of both substances respectively was administered. In the two groups which had been given AT III substitution the concentration of AT III rose considerably higher than the activity. There was a drop of the platelet count in both groups which had received heparin. C1 esterase inhibitor was diminished in the beginning but spontaneously increased in all groups. This increase was slowest in the group without substitution of AT III. The blood loss in cases of traumatic shock was considerably higher in the group which had received both substances. The consumption of AT III concentrates was slightly higher in the combined therapy group than in the AT III group. The duration of symptoms of DIC was considerably shorter in the two substituted groups than in the heparin group. It is concluded that additional administration of heparin does not improve the effect of AT III substitution in patients with DIC and that side effects such as thrombocytopenia and an increased blood loss are likely to develop when both substances are given simultaneously.
D000990:Antithrombin III / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology; D006493:Heparin / Q000627:therapeutic use*; D006501:Hepatic Encephalopathy / Q000150:complications / Q000188:drug therapy; D006801:Humans; D011897:Random Allocation; D012769:Shock / Q000150:complications / Q000188:drug therapy*; D012772:Shock, Septic / Q000150:complications / Q000188:drug therapy; D012774:Shock, Traumatic / Q000150:complications / Q000188:drug therapy
D000990:Antithrombin III; D006493:Heparin